Rapamycin (sirolimus) for treatment of chronic graft-versus-host disease
Open Access
- 31 January 2005
- journal article
- clinical trial
- Published by Elsevier in Transplantation and Cellular Therapy
- Vol. 11 (1) , 47-55
- https://doi.org/10.1016/j.bbmt.2004.10.004
Abstract
No abstract availableKeywords
This publication has 31 references indexed in Scilit:
- Sirolimus, tacrolimus, and low-dose methotrexate for graft-versus-host disease prophylaxis in mismatched related donor or unrelated donor transplantationBlood, 2003
- Sirolimus: a comprehensive reviewExpert Opinion on Pharmacotherapy, 2001
- A high-dose pulse steroid regimen for controlling active chronic graft-versus-host diseaseTransplantation and Cellular Therapy, 2001
- Development of a prognostic model for grading chronic graft-versus-host diseaseBlood, 2001
- SIROLIMUS REDUCES THE INCIDENCE OF ACUTE REJECTION EPISODES DESPITE LOWER CYCLOSPORINE DOSES IN CAUCASIAN RECIPIENTS OF MISMATCHED PRIMARY RENAL ALLOGRAFTS: A PHASE II TRIAL1Transplantation, 1999
- SIROLIMUS (RAPAMYCIN)-BASED THERAPY IN HUMAN RENAL TRANSPLANTATIONTransplantation, 1999
- IMMUNOSUPPRESSIVE EFFECTS AND SAFETY OF A SIROLIMUS/CYCLOSPORINE COMBINATION REGIMEN FOR RENAL TRANSPLANTATION1Transplantation, 1998
- THE EFFECT OF RAPAMYCIN ON KIDNEY FUNCTION IN THE SPRAGUE-DAWLEY RATTransplantation, 1992
- GLUCOCORTICOID THERAPYMedicine, 1976
- Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle.The Journal of Antibiotics, 1975